Shrinking Big Pharma

Why building smaller manufacturing plants is the next big thing


Bigger isn’t always better. In fact, the growing trend in pharma is looking at ways to shrink the industry’s plant-floor footprint down.A few months ago, Amgen announced plans to build a new “next-generation” manufacturing facility in Rhode Island, which will be modeled on the company’s highly innovative plant in Singapore. What makes it cutting edge? Its smaller size. According to Amgen, its Singapore facility occupies about one-fifth the size of a traditional pharma plant but maintains a comparable level of output. It was also built in half the time and at a fraction of the price of a conventional plant ­— a new measure of efficiency Amgen intends to…

Full Story

Don't Miss These Pharma Manufacturing Exclusives


On-demand, concise audio and powerpoint tutorials on the fundamental concepts of pharmaceutical manufacturing, process development, quality control and compliance.

Research Zone

A collection of news stories highlighting advances in medical science and pharmaceutical R&D.

Funny Pharm

Write a caption and win!

Aug15homepageBe sure to check out our newest cartoon created by award-winning artist Jerry King. He provides the artwork; you provide the funny caption!

Most Recent

  • Empty Chamber Studies (aka Much Ado About Nothing)

    By James Agalloco, Agalloco & Associates

    Empty chamber studies have been a part of sterilization validation since its beginnings in the 1970’s. The first regulatory mention of temperature distribution studies in the United States can be found in FDA’s draft Large Volume Parenterals (LVP) CGMP regulation from 1976 (never made official…

    Full Story
  • Top 10 Selling Drugs in 2024

    By Meagan Parrish, Senior Editor

    Which drugs will reign supreme in six years? It’s not too soon to roll out a crystal ball and make predictions.Recently, EvaluatePharma, a market research and consulting firm, released a global forecasting report aiming to do that.Overall, the firm predicts that the pharma industry will continue…

    Full Story
  • The Clock is Ticking: How to Speed up Efforts to Meet Traceability Deadlines

    By Himanshu Jain, NTT DATA Healthcare and Life Sciences

    Starting November 2018, the U.S. Food and Drug Administration (FDA) will begin enforcing the requirement in the Drug Supply Chain Security Act (DSCSA) to include a product identifier on prescription drug packaging.2 The deadline for drugs coming from the EU is about two months later, on Feb. 9,…

    Full Story
  • Bringing Smart Instrumentation to Life Sciences

    By Kyle Knutson, Product Manager for Rosemount Pressure and Hygienic, Emerson Automation Solutions

    The life sciences industries in general and pharmaceutical manufacturing in particular are subject to a wide variety of regulations covering production techniques and equipment design. This isn’t exactly news to anyone in the business, but stop for a moment and consider what it means on a…

    Full Story
  • Pharma’s Reputational Tornado Zone

    By Dr. Nir Kossovsky, CEO, Steel City Re

    Reputational risk is often equated with the risk of negative media coverage and, by that definition, is simply a marketing challenge. But given its complexity, a more accurate way to define reputational risk is to consider it as the risk of economic damage from angry, frightened or disappointed…

    Full Story
  • API Sourcing: Your Questions Answered

    By Jan Batka, API sales director, Saneca Pharma

    What criteria should drug manufacturers consider when choosing API sourcing partners?Generally speaking, manufacturers need to think about the long-term stability of their partner. Can they offer sustained supply of a high-quality product at a competitive price and is their service flexible enough…

    Full Story

Latest Products